Acumen Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 52
- Market Cap
- $168.8M
- Website
- http://www.acumenpharm.com
- Introduction
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
ALS Drug NU-9 Shows Promising Results for Alzheimer's Disease in Animal Study
Northwestern University researchers found that NU-9, an experimental drug approved for ALS clinical trials, effectively reduces toxic protein buildup in Alzheimer's disease animal models.
Acumen Pharmaceuticals Advances Sabirnetug for Alzheimer's, Reports Q3 2024 Financials
Acumen Pharmaceuticals is progressing its Phase 2 ALTITUDE-AD trial of sabirnetug, an immunotherapy for Alzheimer's, with enrollment expected to complete in H1 2025.
Acumen Pharmaceuticals' pTau217 Assay Streamlines Alzheimer's Clinical Trials
Acumen Pharmaceuticals presents data on pTau217 assay for efficient screening in the ALTITUDE-AD trial, reducing the need for invasive procedures.
Acumen Pharmaceuticals Utilizes pTau217 Assay in Sabirnetug Phase 2 Alzheimer's Trial
Acumen Pharmaceuticals is using a validated plasma pTau217 assay to screen participants for its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease.
Acumen and NKGen Present Alzheimer's Research at CTAD 2024
Acumen Pharmaceuticals will present data on using plasma pTau217 assay for screening participants in their Phase 2 ALTITUDE-AD trial.
Acumen and Lonza Expand Collaboration to Advance Sabirnetug for Alzheimer's Disease
Acumen Pharmaceuticals and Lonza have broadened their partnership to include drug product manufacturing for sabirnetug, targeting early Alzheimer's disease.
Acumen Pharmaceuticals Advances Sabirnetug in Alzheimer's Disease Treatment
Acumen Pharmaceuticals is developing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid-beta oligomers, a primary cause of Alzheimer's disease.
Pharmaceutical Industry Leadership Shuffle: Major Executive Appointments Signal Strategic Shifts Across Biotech and Pharma
AbbVie promoted long-time COO Robert Michael to CEO, marking the end of an extensive leadership search with an internal succession plan.